On November 27, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 131)
Collaborative Workspaces: Revised Process for Filing CDR Submissions and Resubmissions
The CADTH Common Drug Review (CDR) is aligning the process for secure file sharing with the pan-Canadian Oncology Drug Review (pCODR) by implementing Collaborative Workspaces, a secure portal to receive and exchange documents with CDR applicants. Collaborative Workspaces will replace CADTH’s current process of receiving CDR submission requirements on CD, DVD or USB and sending information through FileCatalyst for all submissions and resubmissions filed on or after January 2, 2018. Applicants must be registered in advance of submitting materials to CADTH via Collaborative Workspaces.
Note: Registration may take up to two business days; therefore, it is important to have your registration completed before the anticipated date of filing. Once registered, access is granted to a secure submit and contribute page, allowing for the electronic delivery of documents to CADTH.
Important note: If you are already registered for Collaborative Workspaces for pCODR submissions, you will need to request additional access to CDR. To do so, please email email@example.com, or request through the online web form. Registering a second time is not required.
Applicants should consult the following document for the revised process for filing a submission or resubmission using Collaborative Workspaces: Collaborative Workspaces for the CADTH Common Drug Review. For a list of frequently asked questions consult: Frequently Asked Questions for Manufacturers and Designated Consultants.
Important note: Information provided to CADTH as part of the CDR advance notification process, resubmission eligibility inquiries, or general inquiries about the CDR process should continue to be sent to firstname.lastname@example.org.
For more information, please refer to the CADTH website.